Skip to content
naulon
No noticeNo retraction, correction or concern found when last checked on Nov 15, 2026.

Antibody Responses to SARS-CoV-2 mRNA Vaccines Are Detectable in Saliva

Thomas J. Ketas, Devidas Chaturbhuj, Victor M. Cruz Portillo and 17 more

Pathogens and Immunity · 2021

doi:10.1101/2021.03.11.434841 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Vaccines are critical for curtailing the COVID-19 pandemic (1, 2). In the USA, two highly protective mRNA vaccines are available: BNT162b2 from Pfizer/BioNTech and mRNA-1273 from Moderna (3, 4). These vaccines induce antibodies to the SARS-CoV-2 S-protein, including neutralizing antibodies (NAbs) predominantly directed against the Receptor Binding Domain (RBD) (1–4). Serum NAbs are induced at modest levels within ~1 week of the first dose, but their titers are strongly boosted by a second dose at 3 (BNT162b2) or 4 weeks (mRNA-1273) (3, 4). SARS-CoV-2 is most commonly transmitted nasally or orally and infects cells in the mucosae of the respiratory and to some extent also the gastrointestinal tract (5). Although serum NAbs may be a correlate of protection against COVID-19, mucosal antibodies might directly prevent or limit virus acquisition by the nasal, oral and conjunctival routes (5). Whether the mRNA vaccines induce mucosal immunity has not been studied. Here, we report that antibodies to the S-protein and its RBD are present in saliva samples from mRNA-vaccinated healthcare workers (HCW). Within 1–2 weeks after their second dose, 37/37 and 8/8 recipients of the Pfizer and Moderna vaccines, respectively, had S-protein IgG antibodies in their saliva, while IgA was detected in a substantial proportion. These observations may be relevant to vaccine-mediated protection from SARS-CoV-2 infection and disease.

Abstract licence: CC BY-NC-ND

References15

  1. 1.

    Krammer F. SARS-CoV-2 vaccines in development. Nature 586, 516–527 (2020 ).

    Not in our library10.1038/s41586-020-2798-3 (opens in a new tab)

  2. 2.

    Klasse P.J., Nixon D.F. & Moore J.P. Immunogenicity of clinically relevant SARS-CoV-2 vaccines in non-human primates and humans. Sci Adv Online publication (2021 ).

    Not in our library10.1126/sciadv.abe8065 (opens in a new tab)

  3. 3.

    Polack F.P., Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 383, 2603–2615 (2020 ).

    Not in our library10.1056/nejmoa2034577 (opens in a new tab)

  4. 4.

    Baden L.R., Efficacy and safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 384, 403–416 (2021 ).

    Not in our library10.1056/nejmoa2035389 (opens in a new tab)

  5. 5.
  6. 6.
  7. 7.

    Sette A. & Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell 184, 861–880 (2021 ).

    Not in our library10.1016/j.cell.2021.01.007 (opens in a new tab)

  8. 8.

    Yang H.S., Testing-on-a-probe biosensors reveal association of early SARS-CoV-2 total antibodies and surrogate neutralizing antibodies with mortality in COVID-19 patients. Biosens Bioelectron 178, 113008 (2021 ).

    Not in our library10.1016/j.bios.2021.113008 (opens in a new tab)

  9. 9.

    Cerutti A., Chen K. & Chorny A. Immunoglobulin responses at the mucosal interface. Annu Rev Immunol 29, 273–293 (2011 ).

    Not in our library10.1146/annurev-immunol-031210-101317 (opens in a new tab)

  10. 10.
  11. 11.

    Grönblad E.A. Concentration of immunoglobulins in human whole saliva: effect of physiological stimulation. Acta Odontol Scand 40, 87–95 (1982 ).

    Not in our library10.3109/00016358209041120 (opens in a new tab)

  12. 12.

    Zhou D., Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies. Cell Host Microbe (2021 ).

    Not in our library10.1016/j.chom.2021.02.019 (opens in a new tab)

  13. 13.
  14. 14.
  15. 15.

    Honjo K., Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency. Cell Rep Med 2, 100164 (2021 ).

    Not in our library10.1016/j.xcrm.2020.100164 (opens in a new tab)

Cited by papers we hold8

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.